Tirofiban

Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area[1][2][3].

Product Specifications

CAS Number

[144494-65-5]

Product Name Alternative

L700462; MK383

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Integrin

Type

Reference compound

Related Pathways

Cytoskeleton

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/tirofiban.html

Purity

99.95

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(N[C@H](C(O)=O)CC1=CC=C(OCCCCC2CCNCC2)C=C1)(CCCC)=O

Molecular Formula

C22H36N2O5S

Molecular Weight

440.60

Precautions

H315, H319, H335

References & Citations

[1]Giordano A, et al. Tirofiban induces VEGF production and stimulates migration and proliferation of endothelial cells. Vascul Pharmacol. 2014 May-Jun;61 (2-3) :63-71.|[2]Liu X, et al. Effects of tirofiban on the reperfusion-related no-reflow in rats with acute myocardial infarction. J Geriatr Cardiol. 2013 Mar;10 (1) :52-8.|[3]Yates YJ, et al. The effect of tirofiban on microvascular thrombosis: crush model. Plast Reconstr Surg. 2005 Jul;116 (1) :205-8.